Journal of Clinical Oncology, Vol 10, 795-803, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity

RW Gregg, JM Molepo, VJ Monpetit, NZ Mikael, D Redmond, M Gadia and DJ Stewart
Ontario Cancer Treatment and Research Foundation, Ottawa Regional Cancer Center, Canada.

PURPOSE: To identify the major sites of platinum accumulation within neural tissues after treatment with cisplatin and to determine the relationship between cumulative dosage, time, and the development of histopathological and clinical neurotoxicity. PATIENTS AND METHODS: Twenty-one patients treated antemortem with cisplatin had neural tissue harvested at autopsy. Neural tissues were assayed for platinum and examined for histopathologic evidence of neurotoxicity. The relationship between histopathologic neurotoxicity and various pharmacologic parameters was analyzed. RESULTS: Tissue platinum levels were found to be highest in the dorsal root ganglia and lowest in tissue protected by the blood-brain barrier. For peripheral nerve, dorsal root, and dorsal root ganglia, a linear relationship was observed between platinum levels and cumulative dose. Platinum levels in neural tissue were not observed to decrease with time. Histopathologic toxicity closely matched an index of exposure to platinum (cumulative dose and log of time). Clinical and histopathologic neurotoxicity was found to occur with higher accumulations of platinum, with the highest levels found in patients with clinical evidence of neurotoxicity. CONCLUSIONS: The dorsal root ganglia was the most vulnerable neural structure. This is consistent with the clinical presentation of sensory neuropathy in cisplatin neurotoxicity. Central structures of the spinal cord and brain were protected from platinum accumulation. The increasing histopathologic toxicity, with an index of exposure to platinum, suggests that it is retained indefinitely in an actively neurotoxic form. The pharmacologic parameters examined correlate with the development of and are consistent with the clinical and laboratory features of cisplatin neurotoxicity.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Dzagnidze, Z. Katsarava, J. Makhalova, B. Liedert, M.-S. Yoon, H. Kaube, V. Limmroth, and J. Thomale Repair Capacity for Platinum-DNA Adducts Determines the Severity of Cisplatin-Induced Peripheral Neuropathy J. Neurosci., August 29, 2007; 27(35): 9451 - 9457. [Abstract] [Full Text] [PDF]

				R. Benoliel, J. Epstein, E. Eliav, R. Jurevic, and S. Elad Orofacial Pain in Cancer: Part I--Mechanisms Journal of Dental Research, June 1, 2007; 86(6): 491 - 505. [Abstract] [Full Text] [PDF]

				A. Krarup-Hansen, S. Helweg-Larsen, H. Schmalbruch, M. Rorth, and C. Krarup Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies Brain, April 1, 2007; 130(4): 1076 - 1088. [Abstract] [Full Text] [PDF]

				T. Lecomte, B. Landi, P. Beaune, P. Laurent-Puig, and M.-A. Loriot Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy. Clin. Cancer Res., May 15, 2006; 12(10): 3050 - 3056. [Abstract] [Full Text] [PDF]

				R. Kirchmair, D. H. Walter, M. Ii, K. Rittig, A. B. Tietz, T. Murayama, C. Emanueli, M. Silver, A. Wecker, C. Amant, et al. Antiangiogenesis Mediates Cisplatin-Induced Peripheral Neuropathy: Attenuation or Reversal by Local Vascular Endothelial Growth Factor Gene Therapy Without Augmenting Tumor Growth Circulation, May 24, 2005; 111(20): 2662 - 2670. [Abstract] [Full Text] [PDF]

				January 11 Highlight and Commentary Neurology, January 11, 2005; 64(1): 1 - 1. [Full Text] [PDF]

				A. A. Argyriou, E. Chroni, A. Koutras, J. Ellul, S. Papapetropoulos, G. Katsoulas, G. Iconomou, and H. P. Kalofonos Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial Neurology, January 11, 2005; 64(1): 26 - 31. [Abstract] [Full Text] [PDF]

				A. Pace, A. Savarese, M. Picardo, V. Maresca, U. Pacetti, G. Del Monte, A. Biroccio, C. Leonetti, B. Jandolo, F. Cognetti, et al. Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy J. Clin. Oncol., March 1, 2003; 21(5): 927 - 931. [Abstract] [Full Text] [PDF]

				S. Cascinu, V. Catalano, L. Cordella, R. Labianca, P. Giordani, A. M. Baldelli, G. D. Beretta, E. Ubiali, and G. Catalano Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Oncol., August 15, 2002; 20(16): 3478 - 3483. [Abstract] [Full Text] [PDF]

				J. A. Kaltenbach, J. D. Rachel, T. A. Mathog, J. Zhang, P. R. Falzarano, and M. Lewandowski Cisplatin-Induced Hyperactivity in the Dorsal Cochlear Nucleus and Its Relation to Outer Hair Cell Loss: Relevance to Tinnitus J Neurophysiol, August 1, 2002; 88(2): 699 - 714. [Abstract] [Full Text] [PDF]

				J. L. Catalan-Aplandis, N. V. Jimenez-Torres, J. Calpe-Maravilla, and D. Almenar-Cubells Gender and anthropometrics of patients undergoing cisplatin-containing chemotherapy as determinants of acute emesis over repeat courses Journal of Oncology Pharmacy Practice, June 1, 2002; 8(2-3): 89 - 95. [Abstract] [PDF]

				D. Strumberg, S. Brugge, M. W. Korn, S. Koeppen, J. Ranft, G. Scheiber, C. Reiners, C. Mockel, S. Seeber, and M. E. Scheulen Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer Ann. Onc., February 20, 2002; 13(2): 229 - 236. [Abstract] [Full Text] [PDF]

				M. F. Dominguez, R. I. R. Macias, I. Izco-Basurko, A. de la Fuente, M. J. Pascual, J. M. Criado, M. J. Monte, J. Yajeya, and J. J. G. Marin Low in Vivo Toxicity of a Novel Cisplatin-Ursodeoxycholic Derivative (Bamet-UD2) with Enhanced Cytostatic Activity versus Liver Tumors J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1106 - 1112. [Abstract] [Full Text]

				F. Grolleau, L. Gamelin, M. Boisdron-Celle, B. Lapied, M. Pelhate, and E. Gamelin A Possible Explanation for a Neurotoxic Effect of the Anticancer Agent Oxaliplatin on Neuronal Voltage-Gated Sodium Channels J Neurophysiol, May 1, 2001; 85(5): 2293 - 2297. [Abstract] [Full Text] [PDF]

				R. A. Velazquez, Y. Cai, Q. Shi, and A. A. Larson The Distribution of Zinc Selenite and Expression of Metallothionein-III mRNA in the Spinal Cord and Dorsal Root Ganglia of the Rat Suggest a Role for Zinc in Sensory Transmission J. Neurosci., March 15, 1999; 19(6): 2288 - 2300. [Abstract] [Full Text] [PDF]

				R. S. Go and A. A. Adjei Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin J. Clin. Oncol., January 1, 1999; 17(1): 409 - 409. [Abstract] [Full Text] [PDF]

				Media Review: References of Interest for the Pediatric Oncology Nurse Journal of Pediatric Oncology Nursing, January 1, 1992; 9(4): 196 - 198. [PDF]